Upper Respiratory Tract Sarcoidosis
ICD-10 D86.8 · ICD-11 4B20.Y.2

Treatment of Upper Respiratory Tract Sarcoidosis: Biologic Therapy

Upper respiratory tract sarcoidosis is a granulomatous inflammatory condition affecting the nasal passages, sinuses, larynx, and adjacent structures. For patients requiring escalation beyond initial measures, biologic therapy has demonstrated clinical benefit in reducing disease burden.

Treatment Approach
The management approach for this condition involves anti-TNF biologic agents. The complete structured regimen — including specific agent selection, administration schedule, and follow-up — is available in the full protocol.
Instant Access to Structured Evidence-Based Regimens

References

  • Small, short-term studies have shown infliximab to be effective in reducing sarcoidosis symptoms in patients who did not respond to other treatments.
  • Anecdotal reports have shown adalimumab to be effective in reducing sarcoidosis symptoms.
View source ↗